These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 28858522)
21. Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. Chen JB; Chern TR; Wei TT; Chen CC; Lin JH; Fang JM J Med Chem; 2013 May; 56(9):3645-55. PubMed ID: 23570542 [TBL] [Abstract][Full Text] [Related]
22. Methyl effect in azumamides provides insight into histone deacetylase inhibition by macrocycles. Maolanon AR; Villadsen JS; Christensen NJ; Hoeck C; Friis T; Harris P; Gotfredsen CH; Fristrup P; Olsen CA J Med Chem; 2014 Nov; 57(22):9644-57. PubMed ID: 25380299 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases. Henkes LM; Haus P; Jäger F; Ludwig J; Meyer-Almes FJ Bioorg Med Chem; 2012 Jan; 20(2):985-95. PubMed ID: 22182579 [TBL] [Abstract][Full Text] [Related]
24. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors. Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326 [TBL] [Abstract][Full Text] [Related]
26. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. Thaler F; Mercurio C ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063 [TBL] [Abstract][Full Text] [Related]
27. Discovery of the first histone deacetylase 6/8 dual inhibitors. Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185 [TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. Zhang Y; Feng J; Liu C; Fang H; Xu W Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698 [TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents. Cheng J; Qin J; Guo S; Qiu H; Zhong Y Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565 [TBL] [Abstract][Full Text] [Related]
30. A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors. Guerrant W; Mwakwari SC; Chen PC; Khan SI; Tekwani BL; Oyelere AK ChemMedChem; 2010 Aug; 5(8):1232-5. PubMed ID: 20533500 [No Abstract] [Full Text] [Related]
31. Inside HDACs with more selective HDAC inhibitors. Roche J; Bertrand P Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122 [TBL] [Abstract][Full Text] [Related]
32. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1. Xu Z; Hu W; Wang Z; Gou S Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors. Stolfa DA; Stefanachi A; Gajer JM; Nebbioso A; Altucci L; Cellamare S; Jung M; Carotti A ChemMedChem; 2012 Jul; 7(7):1256-66. PubMed ID: 22628266 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors. Narita K; Matsuhara K; Itoh J; Akiyama Y; Dan S; Yamori T; Ito A; Yoshida M; Katoh T Eur J Med Chem; 2016 Oct; 121():592-609. PubMed ID: 27318982 [TBL] [Abstract][Full Text] [Related]
35. Structural basis for the design and synthesis of selective HDAC inhibitors. Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069 [TBL] [Abstract][Full Text] [Related]
36. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983 [TBL] [Abstract][Full Text] [Related]
37. Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. Thaler F; Moretti L; Amici R; Abate A; Colombo A; Carenzi G; Fulco MC; Boggio R; Dondio G; Gagliardi S; Minucci S; Sartori L; Varasi M; Mercurio C Eur J Med Chem; 2016 Jan; 108():53-67. PubMed ID: 26629860 [TBL] [Abstract][Full Text] [Related]
38. A novel series of l-2-benzyloxycarbonylamino-8-(2-pyridyl)-disulfidyloctanoic acid derivatives as histone deacetylase inhibitors: design, synthesis and molecular modeling study. Huang D; Li X; Wei Y; Xiu Z Eur J Med Chem; 2012 Jun; 52():111-22. PubMed ID: 22465091 [TBL] [Abstract][Full Text] [Related]
39. Selective histone deacetylase inhibitors. Pan H; Cao J; Xu W Anticancer Agents Med Chem; 2012 Mar; 12(3):247-70. PubMed ID: 22263804 [TBL] [Abstract][Full Text] [Related]
40. An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. Marcaurelle LA; Comer E; Dandapani S; Duvall JR; Gerard B; Kesavan S; Lee MD; Liu H; Lowe JT; Marie JC; Mulrooney CA; Pandya BA; Rowley A; Ryba TD; Suh BC; Wei J; Young DW; Akella LB; Ross NT; Zhang YL; Fass DM; Reis SA; Zhao WN; Haggarty SJ; Palmer M; Foley MA J Am Chem Soc; 2010 Dec; 132(47):16962-76. PubMed ID: 21067169 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]